These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33418337)

  • 21. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.
    Li J; Liu G; Liu X; Yang J; Chang J; Zhang W; Yu XF
    Viruses; 2015 Jul; 7(7):3891-909. PubMed ID: 26193302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.
    Zhang Z; Dong Z; Wei Q; Carr MJ; Li J; Ding S; Tong Y; Li D; Shi W
    J Virol; 2017 May; 91(9):. PubMed ID: 28250116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.
    In HJ; Lim H; Lee JA; Kim HJ; Kim JW; Hyeon JY; Yeo SG; Lee JW; Yoo JS; Choi YK; Lee SW
    PLoS One; 2017; 12(5):e0178259. PubMed ID: 28542556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71.
    Mao Q; Li N; Yu X; Yao X; Li F; Lu F; Zhuang H; Liang Z; Wang J
    Arch Virol; 2012 Jan; 157(1):37-41. PubMed ID: 21984267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10.
    Yang Q; Ding J; Cao J; Huang Q; Hong C; Yang B
    J Med Virol; 2015 Jun; 87(6):954-60. PubMed ID: 25754274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Establishment of Infectious Clone and Single Round Infectious Particles for Coxsackievirus A10.
    Wang M; Yan J; Zhu L; Wang M; Liu L; Yu R; Chen M; Xun J; Zhang Y; Yi Z; Zhang S
    Virol Sin; 2020 Aug; 35(4):426-435. PubMed ID: 32144688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an efficient neutralization assay for Coxsackievirus A10.
    Liu D; Xu L; Zhu R; Yin Z; Lin Y; Hou W; Li S; He S; Cheng T; Xia N
    Appl Microbiol Biotechnol; 2019 Feb; 103(4):1931-1938. PubMed ID: 30617817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
    Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
    Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 10-Day-Old Murine Model of Coxsackievirus A6 Infection for the Evaluation of Vaccines and Antiviral Drugs.
    Jiang Z; Zhang Y; Lin H; Cheng Q; Lu X; Liu W; Zhou R; Zhong B; Tian X
    Front Immunol; 2021; 12():665197. PubMed ID: 34054834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological evaluation and comparison of different EV71 vaccine candidates.
    Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
    Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Immunogenicity of a Stable, Cold-Adapted, Temperature-Sensitive/Conditional Lethal Enterovirus A71 in Monkey Study.
    Chua KB; Ng Q; Meng T; Jia Q
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33803356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development.
    Chang JY; Chang CP; Tsai HH; Lee CD; Lian WC; Ih-Jen-Su ; Sai IH; Liu CC; Chou AH; Lu YJ; Chen CY; Lee PH; Chiang JR; Chong PC
    Vaccine; 2012 Jan; 30(4):703-11. PubMed ID: 22142585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
    Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
    J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
    Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
    Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of EV71 vaccine candidates.
    Chong P; Hsieh SY; Liu CC; Chou AH; Chang JY; Wu SC; Liu SJ; Chow YH; Su IJ; Klein M
    Hum Vaccin Immunother; 2012 Dec; 8(12):1775-83. PubMed ID: 22992566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally.
    Fan S; Liao Y; Jiang G; Wang L; Zhao H; Yu L; Xu X; Li D; Zhang Y; Li Q
    Vaccine; 2021 Jan; 39(3):596-604. PubMed ID: 33342637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
    Fang CY; Liu CC
    Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.
    Chou AH; Liu CC; Chang CP; Guo MS; Hsieh SY; Yang WH; Chao HJ; Wu CL; Huang JL; Lee MS; Hu AY; Lin SC; Huang YY; Hu MH; Chow YH; Chiang JR; Chang JY; Chong P
    PLoS One; 2012; 7(4):e34834. PubMed ID: 22529942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains.
    Huo Y; Yang J; Liu P; Cui B; Wang C; Liu S; Dong F; Yan X; Bian L; Gao F; Wu X; Zhou J; Cheng T; Li X; Mao Q; Liang Z
    Hum Vaccin Immunother; 2021 Dec; 17(12):5334-5347. PubMed ID: 34756160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.
    Tian X; Su X; Li X; Li H; Li T; Zhou Z; Zhong T; Zhou R
    PLoS One; 2012; 7(7):e41381. PubMed ID: 22848478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.